Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication

被引：4

作者：

Shimony, Shai ^{[1
,2
]}

Mintz, Hilla Reiss ^{[3
]}

Beryozkin, Yulia Shvartser ^{[4
]}

Shoham, Avivit ^{[5
]}

Raanani, Pia ^{[1
,2
]}

Wolach, Ofir ^{[1
,2
]}

机构：

[1] Beilinson Med Ctr, Davidoff Canc Ctr, Inst Hematol, Rabin Med Ctr, Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Beilinson Med Ctr, Div Gastroenterol, Rabin Med Ctr, Petah Tiqwa, Israel

[4] Beilinson Med Ctr, Div Pathol, Rabin Med Ctr, Petah Tiqwa, Israel

[5] Beilinson Med Ctr, Radiol Dept, Rabin Med Ctr, Petah Tiqwa, Israel

来源：

ACTA HAEMATOLOGICA | 2020年 / 143卷 / 01期

关键词：

Acute myeloid leukemia; Midostaurin; Hemorrhagic gastritis;

D O I：

10.1159/000500975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.

引用

页码：65 / 68

页数：4

共 50 条

[1] Midostaurin for the treatment of acute myeloid leukemia
Patnaik, Mrinal M.
FUTURE ONCOLOGY, 2017, 13 (21) : 1853 - 1871
[2] Midostaurin: an emerging treatment for acute myeloid leukemia patients
Gallogly, Molly Megan
Lazarus, Hillard M.
JOURNAL OF BLOOD MEDICINE, 2016, 7 : 73 - 83
[3] Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
Abbas, Hussein A.
Alfayez, Mansour
Kadia, Tapan
Ravandi-Kashani, Farhad
Daver, Naval
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 8817 - 8828
[4] Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Walker, Alison R.
Wang, Hongyan
Walsh, Katherine
Bhatnagar, Bhavana
Vasu, Sumithira
Garzon, Ramiro
Canning, Renee
Geyer, Susan
Wu, Yue-Zhong
Devine, Steven M.
Klisovic, Rebecca
Blum, William
Marcucci, Guido
LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2100 - 2108
[5] ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia
Sucha, Simona
Sorf, Ales
Svoren, Martin
Vagiannis, Dimitrios
Ahmed, Fahda
Visek, Benjamin
Ceckova, Martina
BIOMEDICINE & PHARMACOTHERAPY, 2022, 150
[6] Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Kayser, Sabine
Levis, Mark J.
Schlenk, Richard F.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1177 - 1189
[7] Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin
Dotson, Jennifer
Elhamdani, Adee
Petryna, Ellen
Jamil, Muhammad Omer
Alsharedi, Mohamed
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 351 - 355
[8] Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis
Cairoli, Roberto
Ferrara, Felicetto
Girmenia, Corrado
Luppi, Mario
Pea, Federico
Specchia, Giorgina
Venditti, Adriano
HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 20 - 26
[9] Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
Lucas Gutierrez
Miran Jang
Tian Zhang
Mojtaba Akhtari
Houda Alachkar
Scientific Reports, 8
[10] Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin
Jennifer Dotson
Adee Elhamdani
Ellen Petryna
Muhammad Omer Jamil
Mohamed Alsharedi
International Journal of Hematology, 2019, 109 : 351 - 355

← 1 2 3 4 5 →